Clinical Trials · NCT01253304
A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 26
- Start date
- Nov 2010
- Locations
- 2 sites, Germany, Hungary
- Primary endpoint
- Pharmacokinetics: Maximum Observed Concentration (Cmax)